Lupin, Phil Inc partner to deliver solutions for patients on Solosec® Lupin, Phil Inc partner to deliver solutions for patients on Solosec® 02 February 2021 | News Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the US among adult women Source credit: Lupin Lupin Pharmaceuticals, Inc, a global pharmaceutical company, has announced a partnership with Phil, Inc, which helps deliver cost-effective next-generation access solutions for patients who are prescribed Solosec® (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the US among adult women. This treatment is designed to deliver a full course of therapy in just one packet.